Completed PHASE4 INTERVENTIONAL 1-arm NCT01861613

Seroprevalence of Hepatitis B and Immune Response to Hepatitis B Vaccination in Chinese College Students

Sponsor: Guangxi Center for Disease Control and Prevention

Conditions Hepatitis B Immune Response Seroprevalence

Interventions HBV vaccine (Engerix-B, recombinant hepatitis B surface antigen, 20µg/mL/vial, GlaxoSmithKline, Belgium)

Updated 5 times since 2017 Last updated: May 23, 2013 Started: Sep 30, 2009 Primary completion: Nov 30, 2011

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Listed as NCT01861613, this PHASE4 trial focuses on Hepatitis B and Immune Response and remains completed. Sponsored by Guangxi Center for Disease Control and Prevention, it has been updated 5 times since 2009, reflecting limited change activity. This study is part of the global effort to build evidence for infectious disease interventions.

Status Flow

Change History

5 versions recorded

Sep 2024 — Present [monthly]

Completed PHASE4
Jul 2024 — Sep 2024 [monthly]

Completed PHASE4
Jan 2021 — Jul 2024 [monthly]

Completed PHASE4
Jun 2018 — Jan 2021 [monthly]

Completed PHASE4
Jan 2017 — Jun 2018 [monthly]

Completed PHASE4

First recorded

Sep 2009

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Guangxi Center for Disease Control and Prevention
Hui Zhuang

Data source: Peking University

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Nanning, China